Acrodermatitis Continua of Hallopeau Successfully Treated With Bimekizumab

Bibliographic Details
Published in:	Dermatology Practical & Conceptual
Main Authors:	Andrea Pagliara, Federico Bardazzi, Lidia Sacchelli, Federica Filippi, Camilla Loi, Bianca Maria Piraccini, Giacomo Clarizio
Format:	Article
Language:	English
Published:	Mattioli1885 2024-10-01
Subjects:	psoriasis hallopeau biologics bimekizumab anti-TNF
Online Access:	http://www.dpcj.org/index.php/dpc/article/view/4783

Similar Items

Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab
by: Luigi Gargiulo, et al.
Published: (2023-04-01)

Acrodermatitis Continua of Hallopeau with Bone Resorption in an 8-Year-Old Patient: A Case Report
by: May Alorainy, et al.
Published: (2017-12-01)

Long-term control of refractory acrodermatitis continua of Hallopeau with subcutaneous spesolimab: A case report
by: Jan Nicolai Wagner, MD, et al.
Published: (2025-12-01)

Successful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report
by: Pengfei Wen, et al.
Published: (2024-02-01)

Acrodermatitis continua of hallopeau: aggravating factors and treatment outcomes of 96 patients
by: Liyan Yuan, et al.
Published: (2024-12-01)

Acrodermatitis continua of Hallopeau: a review and update on biological and small molecule targeted immunomodulatory therapies
by: Qiong Sun, et al.
Published: (2025-08-01)

Spesolimab in generalized pustular psoriasis complicated by acrodermatitis continua of Hallopeau: a case report and mechanistic insights
by: Xin-Yi Hou, et al.
Published: (2025-05-01)

Case report: Successful treatment with spesolimab of acrodermatitis continua of Hallopeau in an older patient without IL36RN mutations
by: Jianfeng Zheng, et al.
Published: (2025-01-01)

Apremilast Coadministered with Secukinumab for Effective Treatment of Acrodermatitis Continua of Hallopeau: A Case Report
by: Yao XY, et al.
Published: (2025-05-01)

Acrodermatitis Continua of Hallopeau and Generalised Pustular Psoriasis: Case Reports of Two Different Manifestations of IL36RN Mutation in Siblings
by: Gu M, et al.
Published: (2025-03-01)

A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
by: Matteo Megna, MD, et al.
Published: (2023-08-01)

Pemphigus vegetans of hallopeau
by: Nanda Soni, et al.
Published: (2005-01-01)

Bimekizumab: Short-Term Effectiveness and Safety in Real Clinical Practice in Andalucia, Spain
by: Ricardo Ruiz-Villaverde, et al.
Published: (2024-02-01)

Bimekizumab as-needed dosing in patients with psoriasis: a case series
by: Carlota Abbad-Jaime De Aragón, et al.
Published: (2025-12-01)

Acrodermatitis continua of Hallopeau successfully treated with bimekizumab: A case report
by: Katrina D Cirone, et al.
Published: (2023-03-01)

Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis)
by: D. Orsini, et al.
Published: (2024-12-01)

Successful treatment of severe acrodermatitis continua of hallopeau with Bimekizumab: A case report
by: Lily Xu, et al.
Published: (2025-01-01)

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
by: Luigi Gargiulo, et al.
Published: (2023-08-01)

Rapid response on facial psoriasis to bimekizumab: case series
by: Nicoletta Bernardini, et al.
Published: (2024-05-01)

Real-life Experience of Bimekizumab in 27 Obese Patients With Plaque-type Psoriasis: a 24-week Multicenter Retrospective Study
by: Zeno Fratton, et al.
Published: (2025-01-01)

The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
by: Joshua Burshtein, et al.
Published: (2024-02-01)

Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials
by: Yuanyuan Qiu, et al.
Published: (2023-12-01)

Dermoscopy of acrodermatitis continua of Hallopeau
by: Setu Mittal, et al.
Published: (2023-01-01)

Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study
by: Elena Campione, et al.
Published: (2024-10-01)

Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics
by: E. Mortato, et al.
Published: (2025-12-01)

Predictive factors for early super response to bimekizumab in 341 patients with psoriasis—a 24-week short-term multicenter real-life experience
by: Tubanur Çetinarslan, et al.
Published: (2025-12-01)

Effective treatment of recalcitrant palmoplantar psoriasis in a patient with skin of color using bimekizumab
by: Emily G. Tocco, BS, et al.
Published: (2025-09-01)

Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study—IL PSO (Italian Landscape PSOriasis)
by: Helena Gioacchini, et al.
Published: (2025-05-01)

Acrodermatitis Continua of Hallopeau Successfully Treated with Ustekinumab: A Case Report and Literature Review
by: Shi L, et al.
Published: (2023-04-01)

Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives
by: Camiña-Conforto G, et al.
Published: (2023-06-01)

Challenging case of tinea corporis and faciei in psoriatic patient treated with bimekizumab: The usefulness of mycological screening before biological therapies
by: Terenzio Cosio, et al.
Published: (2024-12-01)

Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
by: Chiricozzi A, et al.
Published: (2019-05-01)

Pustular psoriasis of pregnancy with acrodermatitis continua of hallopeau
by: Akanksha Shah, et al.
Published: (2016-01-01)

Acrodermatitis continua de Hallopeau autolimitada en un paciente con pancreatitis crónica: un reporte de caso
by: Valeria Sofia Soto Ariño, et al.
Published: (2025-04-01)

Adverse events associated with bimekizumab for moderate-to-severe plaque psoriasis: A retrospective, multicenter, post-hoc analysis
by: Nikki Zangenah, BA, et al.
Published: (2025-06-01)

Efficacy of Bimekizumab in the Management of Refractory Erythrodermic Pityriasis Rubra Pilaris: Clinical Insights
by: Sofia Theotokoglou, et al.
Published: (2025-07-01)

Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study
by: Yukari Okubo, et al.
Published: (2025-08-01)

Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study
by: Luca Potestio, et al.
Published: (2025-02-01)

Single-Injection Options for Administering a 320 mg Dose of Bimekizumab: 2 mL Safety Syringe and Auto-injector
by: Michael Sebastian, et al.
Published: (2025-03-01)

Acrodermatitis continua of Hallopeau with psoriatic arthritis treated with biologics and apremilast
by: Shohei Igari, et al.
Published: (2023-09-01)